|
Cocaine Dependence
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these findings suggest that suppression of Src signaling in NAc D2-MSNs, via PRMT6 and H3R2me2a down-regulation, functions as a homeostatic brake to restrain cocaine action, and provide novel candidates for the development of treatments for cocaine addiction.
|
27506785 |
2016 |
|
Cocaine Dependence
|
0.310 |
Biomarker
|
disease |
CTD_human |
Taken together, these findings suggest that suppression of Src signaling in NAc D2-MSNs, via PRMT6 and H3R2me2a down-regulation, functions as a homeostatic brake to restrain cocaine action, and provide novel candidates for the development of treatments for cocaine addiction.
|
27506785 |
2016 |
|
Cocaine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone arginine methylation in cocaine action in the nucleus accumbens.
|
27506785 |
2016 |
|
Cocaine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Histone arginine methylation in cocaine action in the nucleus accumbens.
|
27506785 |
2016 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
|
30332648 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Upregulated PRMT6 was found in various human diseases including cancer.
|
29927001 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
|
30332648 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Upregulated PRMT6 was found in various human diseases including cancer.
|
29927001 |
2018 |
|
Malignant Neoplasms
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
Here, we show that PRMT6, a protein arginine methyltransferase responsible for asymmetric dimethylation of histone H3 arginine 2 (H3R2me2a), negatively regulates DNA methylation and that PRMT6 upregulation contributes to global DNA hypomethylation in cancer.
|
29262320 |
2017 |
|
Primary malignant neoplasm
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
Here, we show that PRMT6, a protein arginine methyltransferase responsible for asymmetric dimethylation of histone H3 arginine 2 (H3R2me2a), negatively regulates DNA methylation and that PRMT6 upregulation contributes to global DNA hypomethylation in cancer.
|
29262320 |
2017 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.
|
26436589 |
2015 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.
|
26436589 |
2015 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
PELP1 and PRMT6 are co-recruited to estrogen receptor target genes, PELP1 knockdown affects the enrichment of histone H3R2 di-methylation, and PELP1 and PRMT6 coordinate to regulate the alternative splicing of genes involved in cancer.
|
24447537 |
2014 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
PELP1 and PRMT6 are co-recruited to estrogen receptor target genes, PELP1 knockdown affects the enrichment of histone H3R2 di-methylation, and PELP1 and PRMT6 coordinate to regulate the alternative splicing of genes involved in cancer.
|
24447537 |
2014 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
We conclude that PRMT6 acts as an oncogene in breast cancer cells, promoting growth and preventing senescence, making it an attractive target for cancer therapy.
|
22987071 |
2012 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Protein arginine methyltransferase-6 (PRMT6) regulates steroid-dependent transcription and alternative splicing and is implicated in endocrine system development and function, cell death, cell cycle, gene expression and cancer.
|
22673335 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Protein arginine methyltransferase-6 (PRMT6) regulates steroid-dependent transcription and alternative splicing and is implicated in endocrine system development and function, cell death, cell cycle, gene expression and cancer.
|
22673335 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
We conclude that PRMT6 acts as an oncogene in breast cancer cells, promoting growth and preventing senescence, making it an attractive target for cancer therapy.
|
22987071 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
These findings show that TSP-1 is a transcriptional repression target of PRMT6 and suggest that neutralizing the activity of PRMT6 could inhibit tumor progression and therefore may be of cancer therapeutic significance.
|
19509293 |
2009 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
These findings show that TSP-1 is a transcriptional repression target of PRMT6 and suggest that neutralizing the activity of PRMT6 could inhibit tumor progression and therefore may be of cancer therapeutic significance.
|
19509293 |
2009 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
SIGNIFICANCE: These findings establish Cre-activated mouse models of three different arginine methyltransferases, PRMT1, CARM1, and PRMT6, which are overexpressed in human cancers, providing a valuable tool for the study of PRMT function in tumorigenesis.<i>See related commentary by Watson and Bitler, p. 3</i>.
|
30352814 |
2019 |